Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
RESEARCH TOOLSreports
Holding IPA?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-$0.06Last Year’s EPS
-$0.11Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 10, 2024
|% Change Since: -4.53%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights several significant strategic advancements, particularly in AI-driven drug discovery and cost efficiency initiatives. However, financial metrics like flat year-over-year revenue and increased operating expenses present challenges. The sentiment is balanced with strong growth potential through strategic moves and partnerships, but tempered by current financial constraints and market recovery challenges.Company Guidance
During ImmunoPrecise Antibodies' Q2 2025 earnings call, significant guidance was provided, emphasizing strategic initiatives for future growth. Key metrics include a stable year-over-year revenue of $6.1 million, with a notable 16% increase from the previous quarter. The company reported a net loss of $2.6 million, or $0.09 per share, compared to a loss of $2.4 million in the previous year. BioStrand, the AI-driven platform, achieved its highest quarterly revenue of $397,000, contributing to a life-to-date revenue of $917,000. The company is implementing cost-saving measures, including relocating its headquarters to Austin, Texas, and pursuing the divestiture of two European wet labs to streamline operations and focus on high-impact growth areas like AI-driven drug discovery. Additionally, the company is enhancing its industry profile through events like the AI-Driven Drug Discovery Summit and introducing groundbreaking analytical applications via its LENSai platform. These strategic moves aim to ensure sustained growth, maximize efficiencies, and increase shareholder value, aligning with a broader rebranding initiative to unify and amplify its presence in the life sciences sector.Strategic Headquarters Relocation
IPA has relocated its headquarters from Victoria, BC, to Austin, Texas, aligning with strategic goals for AI and biotech growth, leveraging Austin's vibrant AI community and semiconductor industry.
AI-Driven Drug Discovery Advancements
Significant progress with the LENSai platform, including AI-driven tools for drug discovery, development, and optimization, increasing scalability and reducing costs.
Progress in TATX-112 Program
The TATX-112 program has identified multiple antibodies capable of targeting TrkB expressing cells, showing potential for treating cancers.
BioStrand Revenue Growth
BioStrand achieved its highest quarterly revenue with $397,000, marking a life-to-date revenue of $917,000, and showing strong demand for AI-driven services.
Cost Efficiency Initiatives
Implementation of cost-saving measures, including renouncement of executive bonuses, reducing redundancies, and pursuing non-dilutive funding.
Collaboration with BioNTech
Partnership with Biotheus, acquired by BioNTech, opens new collaborative opportunities in oncology antibody therapeutics.
---
IPA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IPA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Dec 10, 2024 | $0.42 | $0.40 | -4.76% |
| Sep 16, 2024 | $0.67 | $0.54 | -19.40% |
| Jul 29, 2024 | $0.86 | $0.83 | -3.49% |
| Mar 14, 2024 | $1.63 | $1.59 | -2.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ImmunoPrecise Antibodies (IPA) report earnings?
ImmunoPrecise Antibodies (IPA) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is ImmunoPrecise Antibodies (IPA) earnings time?
ImmunoPrecise Antibodies (IPA) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPA EPS forecast?
IPA EPS forecast for the fiscal quarter 2025 (Q3) is -$0.06.
---